Teva To Pay $270M In Propofol Hepatitis Suits
By Erin Fuchs · February 21, 2012, 4:07 PM EST
Teva Pharmaceuticals Industries Ltd. will spend roughly $270 million on suits claiming the way it packaged its anesthetic Propofol caused a hepatitis C outbreak, Teva told securities regulators Friday, revealing it...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login